接受胶质母细胞瘤放化疗患者放射性淋巴细胞减少的临床预测因素:免疫肿瘤学时代调强放疗的临床实用性
研究纳入2006至2017年接受放疗联合替莫唑胺治疗的胶质母细胞瘤患者336例,定义开始放疗后3个月内总淋巴细胞计数<500/μL为急性重度淋巴细胞减少(ASL)。多变量分析显示计划靶区体积增大与ASL发生率升高独立相关(HR 1.02),IMRT与ASL发生率降低独立相关(HR 0.48);倾向匹配比较显示IMRT组ASL发生率低于3D-CRT组(20% vs 37%,P=.005)。
要点
- 336例胶质母细胞瘤患者中118例(35.1%)发生急性重度淋巴细胞减少(ASL)。
- 计划靶区体积增大与ASL风险升高独立相关(HR 1.02,95%CI 1.00-1.03,P=.042)。
- IMRT与ASL风险降低独立相关(HR 0.48,95%CI 0.27-0.87,P=.015)。
核心结论
- IMRT和较小的计划靶区体积与胶质母细胞瘤放疗联合替莫唑胺后ASL发生率降低显著相关。
- 作者认为基于IMRT的策略对于改善免疫肿瘤学时代的治疗结局是必要的。
研究设计与样本
- 研究纳入2006至2017年接受放疗联合替莫唑胺治疗的胶质母细胞瘤患者336例。
- ASL定义为开始放疗后3个月内总淋巴细胞计数<500/μL。
- 采用逻辑回归分析确定ASL的独立预测因素。
主要发现
- 三维适形放疗(3D-CRT)186例(55.4%),调强放疗(IMRT)150例(44.6%)。
- 放疗期间总淋巴细胞计数下降,并在1年随访期间持续处于低水平,而其他血细胞类型水平恢复。
- 118例(35.1%)发生ASL;中位随访19.3个月,ASL患者总生存显著差于无ASL患者(中位18.2个月 vs 22.0个月,P=.028)。
- 多变量分析显示计划靶区体积增大与ASL发生率升高独立相关(HR 1.02,95%CI 1.00-1.03,P=.042),IMRT与ASL发生率降低独立相关(HR 0.48,95%CI 0.27-0.87,P=.015)。
- 倾向匹配比较显示IMRT组ASL发生率低于3D-CRT组(20% vs 37%,P=.005)。
临床怎么用
- 原文结论指出IMRT和较小的计划靶区体积与ASL发生率降低显著相关。
- 作者认为基于IMRT的策略对于改善免疫肿瘤学时代的治疗结局是必要的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy is currently being examined as a treatment modality for glioblastoma. Maintaining an optimal total lymphocyte count (TLC) after radiotherapy (RT) and using temozolomide may be beneficial in optimizing immunotherapy. However, conventional temozolomide-based chemoradiation is known to induce immunosuppressive effects, including lymphopenia. Therefore, this study aimed to identify potential clinical predictors of acute severe lymphopenia (ASL) in patients receiving chemoradiation for glioblastoma. METHODS: We identified patients with glioblastoma treated with RT plus temozolomide from 2006 to 2017. ASL was defined as a TLC of < 500/μL within 3 months after initiating RT. Independent predictors of ASL were determined using logistic regression. RESULTS: A total of 336 patients were evaluated. Three-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) were used in 186 (55.4%) and 150 patients (44.6%), respectively. TLC decreased during RT and remained persistently low during the 1-year follow-up, whereas the levels of other blood cell types recovered. In total, 118 patients (35.1%) developed ASL. During a median follow-up of 19.3 months, patients with ASL showed significantly worse overall survival than did those without ASL (median, 18.2 vs. 22.0 months; P = .028). Multivariable analysis revealed that increased planning target volume (PTV) was independently associated with increased ASL incidence (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.00-1.03; P = .042), while IMRT was independently associated with decreased ASL incidence (HR, 0.48; 95% CI, 0.27-0.87; P = .015). A propensity-matched comparison showed that the incidence of ASL was lower with IMRT than with 3D-CRT (20% vs. 37%; P = .005). CONCLUSIONS: IMRT and low PTV were significantly associated with decreased ASL incidence after RT plus temozolomide for glioblastoma. An IMRT-based strategy is necessary to enhance treatment outcomes in the immune-oncology era.
引用
- Byun HK, Kim N, Yoon HI, et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era. Radiat Oncol. 2019. PMID: 30917849. doi:10.1186/s13014-019-1256-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。